Arrowhead Research Corporation (Nasdaq:ARWR), announcedtoday that its Chairman & Chief Executive Officer, R. Bruce Stewart,will present at the NanoEquity 2006 conference in Frankfurt, Germany on Tuesday, July 11. The presentation will cover the company's business model and investment strategies.
Mr. Stewart founded Arrowhead Research in 2003 to bring universityinnovations in nanotechnology to market and has guided its growth tothe present. Arrowhead is now operating four majority-ownedsubsidiaries commercializing nanotechnologies in the fields ofnanomedicine, nanoelectronics, and nanomaterials. In addition,Arrowhead is sponsoring nanotechnology development at the CaliforniaInstitute of Technology, Stanford University and Duke University.Previous to Arrowhead, Mr. Stewart's thirty year entrepreneurialcareer included founding Acacia Research Corporation, now comprised ofAcacia Technologies (Nasdaq:ACTG) and CombiMatrix (Nasdaq:CBMX).
Arrowhead Research Corporation is adiversified nanotechnology company structured to commercializeproducts expected to have revolutionary impacts on a variety ofindustries, including materials, electronics, life sciences, andenergy.
There are three strategic components to Arrowhead's businessmodel:
Outsourced R&D Program: Arrowhead identifies patented or patent-pending technologies at universities or government labs and funds additional development of those technologies in exchange for exclusive rights to commercialize the resulting prototypes. Leveraging the resources and infrastructure of these institutions provides Arrowhead with a cost-effective development pipeline. Currently, Arrowhead is supporting efforts in drug discovery tools, stem cell technology and nanoelectronics at the California Institute of Technology, Stanford University and Duke University, respectively.
Commercialization Program: After prototypes have been sufficiently developed in the laboratories, Arrowhead forms or acquires majority-owned subsidiaries to commercialize the technology and provides the subsidiaries with strategic, managerial and operational support. By doing so, each research team is able to maintain focus on its specific technology and each management team can focus on specific markets, increasing the likelihood of successful technological development and commercialization. At present, Arrowhead owns majority interest in subsidiaries commercializing diverse technologies, including anti-cancer drugs, RNAi therapeutics, compound semiconductor materials and nanotube technology.
The Patent Toolbox: Arrowhead has acquired or exclusively licensed patents and patent applications covering a broad range of nanotechnology. The Company actively adds to its intellectual property portfolio.
Safe Harbor Statement under the Private Securities LitigationReform Act of 1995:
This news release contains forward-looking statements within themeaning of the "safe harbor" provisions of the Private SecuritiesLitigation Reform Act of 1995. These statements are based upon ourcurrent expectations and speak only as of the date hereof. Our actualresults may differ materially and adversely from those expressed inany forward-looking statements as a result of various factors anduncertainties, including the recent economic slowdown affectingtechnology companies, the future success of our scientific studies,our ability to successfully develop products, rapid technologicalchange in our markets, changes in demand for our future products,legislative, regulatory and competitive developments and generaleconomic conditions. Our Annual Report on Form 10-K and 10-K/A, recentand forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recentCurrent Reports on Forms 8-K and 8-K/A, our Registration Statements onForm S-3, and other SEC filings discuss some of the important riskfactors that may affect our business, results of operations andfinancial condition. We undertake no obligation to revise or updatepublicly any forward-looking statements for any reason.
Source:
